Arcus Biosciences reported new Nature-published data linking suppression of circulating erythropoietin to treatment response in metastatic clear cell renal cell carcinoma (ccRCC) patients receiving casdatifan. The findings come from ARC-20, evaluating the investigational HIF-2α inhibitor casdatifan in metastatic ccRCC. Arcus reported that the erythropoietin axis provides a mechanistic bridge between target engagement and clinical outcomes. For the broader HIF-2α class, the study helps tighten the translation gap between pathway suppression and therapeutic effect, an area that drives patient selection and endpoint design. Regulators and clinicians increasingly look for biomarker-linked pharmacodynamics in oncology programs; Arcus’ readout adds to that evidence base for next-stage development decisions.